SEC Form 3 FORM 3

## UNITED STATES SECURITIES AND EXCHANGE

COMMISSION Washington, D.C. 20549

OMB APPROVAL

3235-

hours per response:

## **INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF** SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person <sup>*</sup> <u>Pinnow Cole</u>	Requiring Sta (Month/Day/Y	2. Date of Event Requiring Statement (Month/Day/Year) 05/25/2024 3. Issuer Name and Ticker or Trading Symbol Cogent Biosciences, Inc. [ COGT ]						
(Last) (First) (Middle) C/O COGENT BIOSCIENCES, INC.			4. Relationship of Reporting Issuer (Check all applicable)	Person(s) to		5. If Amendment, Date of Original Filed (Month/Day/Year)		
275 WYMAN STREET, 3RD FLOOR			Director X Officer (give title below)		(specify	<ul> <li>Individual or Joint/Group Filing</li> <li>Check Applicable Line)</li> <li>Form filed by One Reporting</li> </ul>		
(Street) WALTHAM MA 02451			Chief Commercia	al Office	er	X Form filed by One Reporting Person Form filed by More than One Reporting Person		
(City) (State) (Zip)								
Table I - Non-Derivative Securities Beneficially Owned								
1. Title of Security (Instr. 4)			. Amount of Securities Beneficially Owned (Instr. )			4. Nature of Indirect Beneficial Ownership (Instr. 5)		
Common Stock			700	D				
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)								
Title of Derivative Security (Instr. 4)2. Date ExercisableExpiration Date (Month/Day/Year)		e	3. Title and Amount of Se Underlying Derivative Sec (Instr. 4)			cise Form: Direct (D) ive or Indirect	6. Nature of Indirect Beneficial Ownership (Instr. 5)	
Evaluation of Responses:	Date Expiration Of Share State Share		Number	Derivative Security				
Explanation of Responses:								

## **Remarks:**

Exhibit 24 - Power of Attorney

/s/ Evan D. Kearns, Attorney-in-Fact \*\* Signature of Reporting

Person

05/29/2024

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.


\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

OMB Number: 0104 Estimated average burden 0.5



## **POWER OF ATTORNEY** For Obtaining EDGAR Access Codes and Executing Forms 3, 4 and 5

Know all by these presents, that the undersigned hereby constitutes and appoints each of Evan Kearns, Ryan Murr and Robert Phillips, and any of their substitutes, signing singly, as the undersigned's true and lawful attorney-in-fact to:

- (1) execute for and on behalf of the undersigned all forms necessary to revive or obtain new EDGAR Access Codes for the undersigned, including without limitation, PMAC, CCC and passwords necessary to enable the undersigned to make filings in the United States Securities and Exchange Commission's EDGAR system;
- (2) execute for and on behalf of the undersigned Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder, and any other forms or reports the undersigned may be required to file, in connection with the undersigned's ownership, acquisition, or disposition of securities of Cogent Biosciences, Inc., a Delaware corporation;
- (3) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete the execution of any such Form 3, 4 and 5, or other form or report, complete and execute any amendment or amendments thereto, and the timely filing of such form with the United States Securities and Exchange Commission and any other authority; and
- (4) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in his/her discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform all and every act and thing whatsoever requisite, necessary and proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as such attorney-in-fact might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or his/her substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by Cogent Biosciences, Inc., unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 16<sup>th</sup> day of May, 2024.

/s/ Cole Pinnow Cole Pinnow